Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vitamin E + silymarin + carnitine is a combination antioxidant and metabolic supplement, often abbreviated as VSC, studied for the treatment of nonalcoholic fatty liver disease (NAFLD), metabolic syndrome, and type 2 diabetes. The formulation typically comprises 200 IU of vitamin E, 750 mg of silymarin, and 1 gram of L-carnitine. It exerts its therapeutic effects through synergistic antioxidant and anti-inflammatory mechanisms, which help reduce markers of liver inflammation (such as ALT and AST), improve insulin sensitivity, and lower triglyceride levels. Clinical research, including studies associated with Biovil Corporation, has evaluated the efficacy of this three-component combination in improving hepatic function and metabolic parameters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitamin e + silymarin + carnitine.